Basilea Pharmaceutica Ltd. revised earnings guidance for the year 2022. The company announced that on preliminary basis it expects to have achieved an operating profit of approximately CHF 18 million for the financial year 2022 and expects to report a net profit. The company had previously guided for an operating loss for 2022 of CHF 10 million to CHF 15 million.

The company announced that the total revenue for 2022 is expected to amount to approximately CHF 148 million, exceeding the previous full-year 2022 guidance of CHF 116 million to CHF 122 million.